Findings from our study showed that females with the CHEK2 I157T GPV have similar cancer risk management practices as those with the CHEK2 1100delC GPV despite lower breast cancer risks that do not reach the threshold for high-risk breast cancer screening. This evidence concerns the gene CHEK2 and breast cancer.